

Contact:

Karen A. Donato, Ph.D.
Vice President, Sales and Marketing
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

***MaxCyte Presents Membrane Protein Expression Data
at the Biophysical Society's Ion Channel Meeting***

Gaithersburg, MD, February 27, 2009 – MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces that there will be a presentation on the MaxCyte® STX™ Scalable Transfection System on Friday, February 27, at the Drug Discovery for Ion Channels Satellite Meeting of the Biophysical Society 53rd Annual Meeting. The title of the presentation is “Expression of Membrane Proteins in Primary Cells and Cell Lines Using a Large Scale Electroporation-Based Transient Transfection Technology.” Authors of the presentation are Dr. Linhong Li, Senior Scientist, and Dr. James Brady, Director of Technical Applications at MaxCyte.

“The MaxCyte STX can effectively load large scale quantities of primary cells and cell lines with plasmids and RNA that express membrane proteins,” says Dr. Brady, who will present the MaxCyte data. “These transiently transfected cells have been shown to perform equivalently to stably transfected cells in cell based assays. The performance of the cells, combined with the flexibility of cell type, loading agent, and scale, makes the MaxCyte STX a valuable tool for the development and conduct of biologically relevant cell based assays.”

“We are delighted that MaxCyte is invited to speak at the Ion Channel Satellite Meeting of the Biophysical Society,” says MaxCyte President and CEO, Doug Doerfler. “The MaxCyte STX has expanded its application to membrane protein expression for cell-based assays. Drug discovery companies are leveraging the efficiency, speed, and operation of the MaxCyte STX in producing billions of modified cells in minutes. Faster development and conduct of cell-base assays increases the productivity of drug discovery groups and increases the likelihood of finding successful drug candidates.”

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte has designed the MaxCyte® STX™ Scalable Transfection System expressly for rapid, scalable, and reagent-free cell transfection for cell based assays and other cell-based applications.

For more information, <http://www.maxcyte.com/cell-based-screening.shtml>.